Table 1

Patient demographic and disease characteristics at inclusion and at cessation of infliximab in the initial versus delayed infliximab treatment group

All (n=104)Initial (n=77)Delayed (n=27)p Value
Female gender (n (%))68 (65)47 (61)21 (78)0.12
Age (years)56 (46–61)56 (45–61)55 (50–62)0.83
RF positive (n (%))68 (65)45 (58)23 (85)0.012
ACPA positive (n (%))76 (73)56 (73)20 (74)0.89
SE positive (n (%))*66 (75)48 (74)18 (78)0.67
Smoking positive (n (%))36 (35)22 (29)14 (52)0.029
BMI (kg/m2)26 (23–28)26 (23–27)26 (23–28)0.59
Symptom duration at cessation (months)23 (15–35)19 (13–27)44 (33–64)<0.001
Infliximab treatment duration at cessation (months)11 (9–17)9 (8–14)16 (11–23)<0.001
DAS at inclusion (mean (SD))4.2 (0.8)4.1 (0.7)4.7 (0.9)<0.001
DAS at cessation (mean (SD))1.3 (0.6)1.3 (0.6)1.4 (0.6)0.50
Remission at cessation (n (%))69 (66)51 (66)18 (69)0.78
HAQ at inclusion1.3 (0.9–1.7)1.3 (0.8–1.8)1.1 (1.0–1.5)0.72
HAQ at cessation0.1 (0.00–0.6)0.2 (0.0–0.5)0.4 (0.1–0.9)0.012
SHS at inclusion3.5 (0.5–10.5)4.8 (0.5–10.9)1.5 (0.5–9.0)0.40
SHS at cessation5.5 (1.0–16.0)4.8 (0.5–13.9)13.0 (3.0–30.6)0.029
  • Data are presented as median (IQR), unless stated otherwise.

  • * SE had missing data for 16 patients.

  • ACPA, anti-citrullinated protein antibodies; BMI, body mass index; DAS, disease activity score; HAQ, health assessment questionnaire; RF, rheumatoid factor; SE, shared epitope; SHS, Sharp/van der Heijde score.